The Food and Drug Administration (FDA) has approved Aczone (dapsone; Almirall) Gel 7.5% for the topical treatment of acne vulgaris in patients aged ≥9 years. Previously, the treatment had been indicated for patients 12 years of age and older.
Cuts are being proposed for 5 controlled substances based on estimates of diversion.
A greater proportion of patients with moderate to severe plaque psoriasis achieved complete skin clearance with ixekizumab when compared with guselkumab, according to results from a phase 4 head-to-head study.
The FDA has expanded the approval for Taclonex Topical Suspension and Enstilar Foam, two plaque psoriasis therapies to include younger patients.
Duobrii (halobetasol propionate and tazarotene; Ortho Dermatologics) has been made available for the topical treatment of plaque psoriasis in adult patients.
Zenatane, a therapeutic equivalent to Accutane, is approved for marketing only under a special restricted distribution as it can cause severe birth defects.
Top-line results were announced from a phase 3 study evaluating the safety and efficacy of abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis in patients ≥12 years old.
A recent report published in the American Journal of Case Reports describes a rare case of drug reaction with eosinophilia and systemic symptoms (DRESS)-induced agranulocytosis in a patient treated with the beta-lactam antibiotic oxacillin.
